Elevation Oncology, Inc. (ELEV): Price and Financial Metrics


Elevation Oncology, Inc. (ELEV): $3.03

-0.32 (-9.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ELEV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ELEV Stock Price Chart Interactive Chart >

Price chart for ELEV

ELEV Price/Volume Stats

Current price $3.03 52-week high $16.22
Prev. close $3.35 52-week low $2.28
Day low $2.92 Volume 462,800
Day high $3.40 Avg. volume 344,746
50-day MA $2.89 Dividend yield N/A
200-day MA $5.80 Market Cap 70.46M

Elevation Oncology, Inc. (ELEV) Company Bio


Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.


ELEV Latest News Stream


Event/Time News Detail
Loading, please wait...

ELEV Latest Social Stream


Loading social stream, please wait...

View Full ELEV Social Stream

Latest ELEV News From Around the Web

Below are the latest news stories about Elevation Oncology Inc that investors may wish to consider to help them evaluate ELEV as an investment opportunity.

Elevation Oncology Highlights 2021 Achievements and Outlines Expected 2022 Milestones

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today highlighted its 2021 corporate achievements and outlined its expected milestones for 2022. Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer, will present these corporate priorities on Wednesday, January 12, 2022, at 9:45 a.m. ET at the virtual 40th Annual J.P. Morgan Healthcare Conference.

Yahoo | January 10, 2022

Elevation Oncology to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Elevation Oncology's Founder and Chief Executive Officer, will participate in a pre-recorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference.

Yahoo | January 6, 2022

Elevation Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Elevation Oncology's Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 9:45 a.m. ET, in a virtual format.

Yahoo | January 5, 2022

H.C. Wainwright Thinks Elevation Oncology’s Stock is Going to Recover

In a report released today, Michael King from H.C. Wainwright initiated coverage with a Buy rating on Elevation Oncology (ELEV – Research Report) and a price target of $12.00. The company's shares closed last Wednesday at $4.90, close to its 52-week low of $4.15. According to TipRanks.com, King is a 5-star analyst with an average return of 20.0% and a 50.6% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. Elevation Oncology has an analyst consensus of Strong Buy, with a price target consensus of $17.67.

Howard Kim on TipRanks | December 23, 2021

Elevation Oncology, Inc.s (NASDAQ:ELEV) Lock-Up Period Set To Expire on December 22nd

Elevation Oncologys (NASDAQ:ELEV) lock-up period will expire on Wednesday, December 22nd. Elevation Oncology had issued 6,250,000 shares in its IPO on June 25th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade []

Transcript Daily | December 22, 2021

Read More 'ELEV' Stories Here

ELEV Price Returns

1-mo -5.61%
3-mo -11.14%
6-mo -54.84%
1-year N/A
3-year N/A
5-year N/A
YTD -49.67%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7654 seconds.